Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.
Fei KongXiaoyu WenXiaofeng WenXiaozhong WangGuicheng WuShide LinLi WangHuichun XingXuebing YanSujun ZhengQin NingZheng WangLiaoyun ZhangJianmei LinZhaowei TongChengyu HuangMinghua SuLixin TongJidong JiaYong-Ning XinQingjing ZhuJing WangLi ChenXiaowen LiXuegang WuDuan NiuQuan LiuWei WeiYuexin ZhangGuangming LiJunqi NiuPublished in: Journal of gastroenterology and hepatology (2021)
The all-oral, ribavirin-free regimen of seraprevir and sofosbuvir is an effective and well-tolerated treatment option for Chinese patients mono-infected with HCV, including those with a history of interferon treatment.